Early Biomarkers and Regulatory Innovation in Multidrug-Resistant Tuberculosis

Clinical Infectious Diseases

Volumn 61, Issue , 2015, Pages S160-S163

  Wallis, Robert S ^a   Peppard, Thomas ^b  

^a AURUM INSTITUTE   (South Africa)

^b NONE   (United States)

Author keywords

biomarkers; drug resistance; regulatory innovation; sputum culture; Tuberculosis

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; DEATH; DIAGNOSTIC ACCURACY; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RELAPSE; RISK BENEFIT ANALYSIS; SPUTUM CULTURE; TREATMENT DURATION; TREATMENT FAILURE; DIAGNOSTIC TEST APPROVAL; DRUG APPROVAL; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; LEGISLATION AND JURISPRUDENCE; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PHASE 3 CLINICAL TRIAL (TOPIC); SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; BIOMARKERS; CLINICAL TRIALS, PHASE III AS TOPIC; DIAGNOSTIC TEST APPROVAL; DRUG APPROVAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84943370830     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ612     Document Type: Article

References (27)

1. Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacinbased regimens for drug-sensitive tuberculosis. N Engl J Med 2014; 371:1577-87.
2. Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014; 371:1588-98.
3. Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014; 371:1599-608.
4. Hicks D. How can I miss you when you won't go away [Audio recording]. Recorded by Dan Hicks and His Hot Licks in 1969. Epic/Sony Music; Japan International. Available at: https://vimeo.com/8931252. Accessed 4 August 2015.
5. Gelmanova IY, Ahmad Khan F, Becerra MC, et al. Low rates of recurrence after successful treatment of multidrug-resistant tuberculosis in Tomsk, Russia. Int J Tuberc Lung Dis 2015; 19:399-405.
6. Biomarkers working group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95.
7. Benator D, BhattacharyaM, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360:528-34.
8. Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med 2015; 3:201-9.
9. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months [letter]. Am Rev Respir Dis 1993; 147:1062-3.
10. Wallis RS,Wang C, Doherty TM, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 2010; 10:68-9.
11. Phillips PP, Fielding K, Nunn AJ. An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One 2013; 8:e63840.
12. Wallis RS, Wang C, Meyer D, Thomas N. Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a metaregression model. PLoS One 2013; 8:e71116.
13. Wang JY, Wang JT, Tsai TH, et al. Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int J Tuberc Lung Dis 2010; 14:65-71.
14. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180:273-80.
15. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373:1183-9.
16. Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12:128-38.
17. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174:331-8.
18. Wallis RS, Peppard T, Hermann D. Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update. PLoS One 2015; 10:e0125403.
19. Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res 2008; 14:5967-76.
20. Chen RY, Dodd LE, Lee M, et al. PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci Transl Med 2014; 6:265-166.
21. Coleman MT, Chen RY, Lee M, et al. PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Sci Transl Med 2014; 6:265-167.
22. Bloom CI, Graham CM, Berry MP, et al. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS One 2012; 7:e46191.
23. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466:973-7.
24. Spellberg B, Shlaes D. Prioritized current unmet needs for antibacterial therapies. Clin Pharmacol Ther 2014; 96:151-3.
25. Obama B. Executive Order-combating antibiotic-resistant bacteria. Office of the President, Washington, DC, 2014. Available at: http://www. whitehouse.gov/the-press-office/2014/09/18/executive-order-combatingantibiotic-resistant-bacteria. Accessed 19 February 2015.
26. Holdren JP, Lander E. Report to the President on combating antibiotic resistance. President's Council of Advisors on Science and Technology, Washington, DC, 2014. Available at: http://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast-carb-report-sept2014.pdf. Accessed 19 February 2015.
27. Hatch O, Bennet M. PATH act, 2014. US Senate bill 2996. Available at: http://www.hatch.senate.gov/public/-cache/files/bc6244f3-f993-4ca2-924c-a9b3683db07d/PATH%20Act%20(as%20introduced%2012.10.(14).pdf. Accessed 19 February 2015.